| Expression pattern: |
UP |
| Associated gene: |
IL6ST, IL-1beta, claudin-1, E-cadherin |
| Associated microRNA: |
miR-622 |
| Biological function: |
circUBXN7 promotes LPS-stimulated inflammatory responses and epithelial barrier dysfunction in A549 and Beas-2B cells; inhibition of circUBXN7 mitigates inflammation and cellular barrier damage, whereas overexpression exacerbates these effects. |
| Molecular mechanism: |
circUBXN7 competitively binds miR-622, impairing miR-622 regulatory function on target genes and facilitating LPS-stimulated inflammation and epithelial barrier damage. |
| Biological pathway or process: |
inflammation (promotes); other pathway/process (promotes); ceRNA regulation (other); JAK/STAT (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; FISH / smFISH; Clinical Sample Validation; Transfection; Western Blot; IF (Immunofluorescence); ELISA; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
circUBXN7 may serve as a prognostic biomarker for ARDS; elevated circUBXN7 levels may predict poorer outcomes and showed an AUC of 0.856 for 28-day outcome prediction. |
| Description: |
circUBXN7 is up-regulated in plasma from ARDS patients and further elevated in severe ARDS and non-survivors, supporting its potential value as a prognostic biomarker. Functionally, circUBXN7 promotes LPS-induced inflammatory cytokine expression and epithelial barrier damage in A549 and Beas-2B cells. Mechanistically, it acts through competitive binding to miR-622, thereby weakening miR-622-mediated regulation of downstream target genes. |
| Confidence score: |
0.6719 |